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Abstract: Type I interferon (IFN-I) is the first line of mammalian host defense against viral infection.
To counteract this, the flaviviruses, like other viruses, have encoded a variety of antagonists,
and use a multi-layered molecular defense strategy to establish their infections. Among the most
potent antagonists is non-structural protein 5 (NS5), which has been shown for all disease-causing
flaviviruses to target different steps and players of the type I IFN signaling pathway. Here,
we summarize the type I IFN antagonist mechanisms used by flaviviruses with a focus on the role of
NS5 in regulating one key regulator of type I IFN, signal transducer and activator of transcription 2
(STAT2).
Keywords: flavivirus; ZIKV; NS5; type I IFN antagonist
1. Introduction
Flaviviruses are globally significant arthropod-borne viruses that cause disease in hundreds of
millions of people each year. The Flavivirus genus is part of the Flaviviridae family and comprises over
70 species, including dengue, Zika, yellow fever, West Nile, Japanese encephalitis, and tick-borne
encephalitis viruses. Facilitated by the warming climate, urbanization, and increasing travel to endemic
areas, many of these pathogens have expanded into new territories, and flaviviral infections have
increased worldwide [1]. Despite the enormous burden on public health posed by flaviviruses, there are
currently no antiviral therapies available and limited vaccines.
To establish successful infection in vertebrates, flaviviruses must first overcome the host antiviral
response, which is primarily mediated by type I interferons (IFN-I) [2]. IFN-I stimulates expression
of hundreds of genes that disrupt various stages of the viral life cycle. The power and importance of
this host defense is demonstrated by the fact that all flaviviruses have evolved elaborate mechanisms
to antagonize and evade the type I IFN response. The ability of individual viruses to suppress this
pathway determines host and tissue tropisms and severity of disease [3,4]. Therefore, understanding
the interaction between the host immune response and viral antagonism of this defense at the molecular
level elucidates mechanisms of pathogenesis and facilitates the development of safe and effective
antiviral therapies and vaccines.
Flaviviruses employ diverse strategies to subvert the host immune system. To avoid being
recognized as “non-self,” which triggers IFN-I production, flaviviruses mask their genome with RNA
caps that mimic that of the host and the intermediate RNAs are hidden from cytoplasmic sensors by
membranes hijacked by viral replication proteins [5]. Flaviviruses also actively antagonize proteins
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that function within the IFN-I signaling pathway by inhibiting their post-translational modifications,
competing for protein–protein interactions, or targeting them for degradation [2]. These diverse
mechanisms of IFN antagonism are typically carried out by flavivirus non-structural proteins.
Non-structural protein 5 (NS5) is the largest and most conserved flavivirus protein [6]. It is
responsible for replicating and capping the viral genome, but is also a potent innate immune antagonist
in all flaviviruses studied thus far [7]. However, the mechanisms utilized by the NS5 proteins from
related viruses have been shown to diverge significantly. This review discusses the IFN-I-mediated
defense mounted by flavivirus-infected hosts and the various mechanisms employed by flaviviruses
to counteract this defense, with special emphasis given to NS5-mediated suppression of human signal
transducer and activator of transcription 2 (hSTAT2)-dependent IFN signaling. Three of the major
disease-causing flaviviruses’ NS5 proteins interact with and inhibit hSTAT2, a central regulator of the
type I IFN response. We discuss the ways in which this interaction diverges among the highly related
flaviviruses and the impact of hSTAT2 inhibition on viral pathogenesis.
2. Flavivirus Disease and Transmission
Disease caused by flaviviruses ranges from mild symptoms such as fever, rash, and joint pain to
more severe illness that includes hemorrhagic fever, encephalitis, and neurological sequelae. However,
very few infected individuals experience serious illness, and most are entirely asymptomatic. It is
currently not possible to predict an individual’s disease outcome due to our inadequate understanding
of the molecular basis of the pathogenesis of severe disease. There are no vaccines available for
dengue, Zika, or West Nile viruses. Even for flaviviruses with effective vaccines, such as yellow fever,
Japanese encephalitis, and tick-borne encephalitis viruses, outbreaks still occur from time to time in
developing countries.
Dengue virus (DENV) is responsible for the highest incidence of disease among the flaviviruses
(≈400 million annually) [8]. There are four genetically distinct serotypes of DENV and infection with
one serotype confers long-lasting immunity against only the infecting serotype. Primary infections are
frequently asymptomatic but can result in fever and rash, whereas secondary infections, especially
with a heterologous serotype, can cause dengue hemorrhagic fever and shock syndrome, likely due
to antibody-dependent enhancement (ADE) [9]. Zika virus (ZIKV), which emerged recently in
several major epidemics in Asia and the Americas, causes similar symptoms to dengue fever and
has additionally been causally linked to congenital microcephaly and Guillain-Barré syndrome [10].
West Nile virus (WNV) is common in Africa, the Middle East, and Europe, and appeared in North
America in 1999 [11]. In addition to febrile illness, WNV is a major cause of viral encephalitis [12].
The human pathogen flaviviruses are vector-borne, although different tick and mosquito species
are utilized by different viruses. Yellow fever virus (YFV), DENV, and ZIKV are transmitted primarily
by Aedes mosquitoes [13], whereas WNV and Japanese encephalitis virus (JEV) are transmitted
through the Culex species [14,15]. Flaviviruses are also zoonotic and rely on non-human animal
vectors for widespread circulation. For example, pigs and birds are amplifying hosts for JEV [16],
and non-human primates are ZIKV amplification hosts [17]. Flaviviruses alternate between two distinct
transmission cycles: sylvatic and urban. The sylvatic transmission cycle refers to the transmission
of the virus between the arboreal vector and non-human animal hosts, and the urban cycle consists
of circulation between arthropods and humans [18]. The recent ZIKV epidemics have revealed
additional mechanisms of transmission that may be unique to Zika, such as sexual contact and
perinatal transmission [19,20].
Because of the necessity of alternating between vertebrate and arthropod hosts, flaviviruses have
adapted their immune restriction mechanisms for distinct species. For example, DENV proteins can
cleave the human immune factors stimulator of interferon genes (STING) and STAT2 (discussed below)
but not non-human primate STING or murine STAT2 [3,21,22]. Similarly, ZIKV causes the degradation
of human but not murine STAT2 [3]. These species-specific immune suppression mechanisms help
to explain in part why DENV fails to reach high titers non-human primate models [23,24], and why
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immunocompetent mice are poor disease models for many flaviviruses, including ZIKV and DENV [25,
26].
3. Flavivirus Genome and Life Cycle
Flavivirus genomes are 10-11 kb single-stranded positive-sense RNA molecules flanked by
structured 5’ and 3’ UTRs. A recent study demonstrated pervasive higher-order structures throughout
the ZIKV [27] and DENV2 RNA genomes, spanning at least eight distinct regions [28]. A virally
encoded methyltransferase provides a m7GpppN cap structure to the 5’ end of the genome similar to
mammalian mRNA caps [29], but the flaviviral genome lacks a 3’ polyadenylation tail. The genome is
translated as a single polyprotein, which is then proteolytically processed by host and viral proteases
to generate three structural proteins (capsid (C), pre-membrane (prM), and envelope (E)), and seven
non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). The non-structural (NS)
proteins are responsible for replication of the viral genome, polyprotein processing, and host immune
response antagonism. Mature virions are ≈50 µm in diameter and consist of the RNA genome
encapsulated by a lipid envelope and the three structural proteins C, prM, and E [6].
Flaviviruses enter the cell via endocytosis and traffic to endosomes where the envelope protein
undergoes a low pH-induced conformational change to induce fusion of the endosomal membrane
with the viral membrane. This fusion event allows the nucleocapsid to be released from the endosome,
and the genome is rapidly translated at the surface of the endoplasmic reticulum (ER) [30]. The viral
NS proteins facilitate the formation of replication complexes by hijacking host cytoplasmic membranes.
These compartments coordinate the replication and translation of the viral genome and help to shield
viral components from host recognition. The NS proteins form a replication complex that generates
negative-sense RNAs that function as templates for positive-sense genome RNA. Newly synthesized
viral RNA is packaged, and the immature virion is transported through the host secretory pathway
where it is further processed by host proteases to generate a mature virion that is released from the
infected cell by exocytosis [6].
4. Host Innate Immune Response to Flavivirus Infection
The type I IFN signaling pathway is one of the first lines of defense against flavivirus infection
of mammals. Type I IFNs are produced by mammalian cells in response to viral infection and
play a pivotal role in counteracting viral pathogenesis [31]. Flavivirus-infected individuals have
elevated levels of immune-related gene transcripts and serum IFN [32–36]. In mouse and cell models,
similar elevations have been reported [37–39] and production has been shown to play a protective
role [10–13]. Several proteins that function within this signaling pathway have been identified with
direct and specific antiviral roles during flavivirus infection [37,38,40,41]. IFN-I has even been tested
as a treatment for clinical flavivirus disease, but has not been successful [42,43]. This may be explained
by the universal ability of flaviviruses to inhibit the Janus kinase-signal transducer and activator of
transcription (JAK-STAT) pathway. As discussed below, the NS proteins are the primary actors in
this suppression, and understanding the molecular mechanisms mediating this suppression would
contribute to the development of effective antiviral therapies.
The innate immune response against flaviviruses is triggered by sensing the pathogen-associated
molecular patterns (PAMPs) via the cytosolic and endosomal pattern recognition receptors (PRRs)
retinoic acid-inducible gene-1 (RIG-I), melanoma differentiation-associated protein 5 (MDA5),
Toll-like receptor (TLR) 7/8, or TLR3 [44–46]. PAMP sensing PRRs activate various kinases including
inhibitor of nuclear factor kappa-B (NF-κB) kinase subunit epsilon (IKKε), tumor necrosis factor (TNF)
receptor-associated factor (TRAF) family member-associated NF-κB (TANK)-binding kinase-1 (TBK-1),
and TRAF3, which ultimately result in the phosphorylation of NF-κB and interferon regulatory factor
3 (IRF3) [45,47]. Activated NF-κB and IRF3 translocate to the nucleus to stimulate the production of
type I IFNs.
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The type I IFNs consist primarily of two secreted cytokines, IFN-α and IFN-ß. Upon secretion,
IFN-α/ß bind to their cognate receptor IFNAR on infected and neighboring cells. IFNAR consists
of two subunits (IFNAR1 and IFNAR2) whose intracellular domains are constitutively associated
with the Janus kinases JAK1 and Tyk2. IFN binding to IFNAR activates JAK1 and Tyk2 to
phosphorylate the latent cytoplasmic signal transducers of activation 1 and 2 (STAT1 and STAT2).
Tyrosine phosphorylated STAT1 and STAT2 dimerize and then associate with a third protein, interferon
regulatory factor 9 (IRF9). This trimeric complex, known as interferon-stimulated gene factor 3 (ISGF3),
translocates into the nucleus where it binds to interferon stimulated response elements (ISRE) to drive
transcription of over 300 interferon stimulated genes (ISGs) that directly or indirectly counter flavivirus
infection. IRF9 binds to the ISRE, STAT2 contributes a potent transactivation domain, and STAT1
stabilizes the complex through additional DNA interactions [48,49].
The components of ISGF3 are constitutively expressed at a low level and reside in the cytoplasm in
their latent forms. Upon IFN stimulation and tyrosine phosphorylation of STATs 1 and 2, ISGF3 rapidly
assembles and directs a robust, transient antiviral response that includes the upregulation of ISGF3
components themselves. This response, however, additionally increases the expression of pro-apoptotic
and anti-proliferative genes that can be damaging to the host cell, so downregulation of these
genes occurs quickly after IFN stimulation. This response is mediated by several negative feedback
mechanisms, such as the suppressor of cytokine signaling (SOCS) proteins, which are also induced by
type I IFN [50]. In contrast, a subset of the antiviral ISGs upregulated by the initial IFN stimulation,
including STAT1, STAT2, and IRF9, are sustained for several days, resulting in increased levels of
the unphosphorylated forms of these proteins [51]. These proteins interact to form the trimeric
unphosphorylated ISGF3 (U-ISGF3), which is responsible for the sustained ISG transcription, allowing
for extended resistance to viral infection [52].
Recently, evidence has emerged for the existence of STAT1-independent complexes that can
drive IFN-I-stimulated ISG expression [53]. For example, STAT2 can interact with IRF9 to form an
“ISGF3-like” complex that activates ISRE-promoted genes in response to type I IFN [54]. This complex
can direct a similar but prolonged ISGF3-like transcriptome in the absence of STAT1. However,
some STAT2/IRF9-specific ISGF3-independent ISGs have been identified, including CCL8 and CX3CL1.
The promoter regions of these genes do not contain the classical ISRE sequences, suggesting that a DNA
sequence distinct from ISRE may be involved in STAT2/IRF9-specific gene regulation. Additionally it
has been demonstrated that this alternative pathway can mediate antiviral responses to several viruses
including dengue, vesicular stomatitis, encephalomyocarditis, measles, Crimean-Congo hemorrhagic
fever, and lymphocytic choriomeningitis viruses [55–59]. The cyclic guanosine monophosphate
(GMP)–adenosine monophosphate (AMP) synthase (cGAS) is a cytosolic DNA sensor that directs the
synthesis of cyclic GMP-AMP (cGAMP) upon binding to DNA. cGAMP activates the stimulator of
the IFN gene (STING), which promotes type I IFN production via IRF3 activation [60]. It was recently
demonstrated that the cGAS/STING pathway becomes activated during DENV infection, even in the
absence of viral DNA intermediates [21]. DENV infection induces mitochondrial swelling, causing the
release of mitochondrial DNA, which activates cGAS [61]. The involvement of the cGAS/STING
pathway in other flavivirus infections has yet to be determined.
Although type I IFNs are produced by nearly all cells in the body and are essential for restricting
viral replication, two additional IFN signaling pathways exist and have been shown to respond to
viral infection. The type III IFNs (IFN-λ1-4) are the primary antiviral IFNs generated by epithelial
cells and have similar functions and signaling pathways as IFN-I, but the cellular receptor is not
ubiquitously expressed [62]. An antiviral effect for IFN-λ has been demonstrated for West Nile
and Zika viruses. Mice deficient in the IFN-λ receptor exhibited increased blood–brain barrier
(BBB) permeability after WNV infection [63], suggesting type III IFN signaling is involved in WNV
neurotropism. Primary human trophoblast cells from human placenta were found to release type III
IFN constitutively, conferring resistance to ZIKV infection [64]. The ability of ZIKV to be vertically
transmitted from mother to fetus suggests the existence of a viral factor that may be able to overcome
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the type III IFN response in placental cells. The NS5 protein from ZIKV is a likely candidate as it was
shown to inhibit the type III response in HEK293T cells [65].
While ZIKV NS5 was shown to suppress both the type I and III IFN responses, it was also able to
activate type II IFN signaling [65]. The type II IFNs (IFN-γ) are generated mainly by immune cells
and have some antiviral functions. ZIKV infection, however, is enhanced by type II IFN signaling,
which generates proinflammatory cytokines that can facilitate viral spread and exacerbate Zika
disease [66]. The concurrent NS5-mediated suppression of type I and III pathways and activation of
the type II pathway was suggested to occur through increased homodimerization of STAT1, which
upregulates gene expression at γ-activated sites (GAS). Because ZIKV NS5 induces the degradation of
STAT2 (discussed below), which is required for the formation of transcription complexes involved
in type I and III IFN signaling, the intracellular balance of STAT-containing complexes shifts to
STAT1-STAT1 dimers, resulting in increased IFN-γ-induced gene expression. To date, ZIKV NS5 is the
only viral protein known to concurrently suppress type I and III IFN pathways while activating type
II [65].
5. Flavivirus Antagonism of Host Type I IFN Response
Just as hosts have evolved multiple mechanisms for inhibiting viral infection, viral proteins have
gained the ability to antagonize the host IFN response over time. One mechanism by which the
type I IFN response is passively avoided by flaviviruses is evasion of the host PRRs, described above.
Flaviviruses encode their own methyltransferase that caps the RNA genome to mimic the RNAs present
in the host cell. The cap structure hides the viral genome from members of the interferon-induced
tetratricopeptide repeats (IFIT) protein family, which binds to and sequesters viral RNA, and prevents
recognition by the RIG-I [67]. Flaviviruses also shield their genome from host sensing by enclosing
their replication complex (RC) in membranes on the ER surface, a mechanism that has been observed in
the early stages of DENV, WNV, and tick-borne encephalitis virus (TBEV) infections [68,69]. However,
late in the infection, newly synthesized viral RNA is abundant, and the RC loses some integrity,
which may lead to the release of RNA intermediates that could activate RIG-I or MDA5 signaling [70].
Flaviviruses have also been demonstrated to actively abrogate the activity of protein functioning
within the type I IFN signaling pathway. One common mechanism is interference with
post-translational modifications of these proteins. For example, the DENV, WNV, and YFV NS4B
inhibit STAT1 phosphorylation [71,72]. WNV NS4B is additionally implicated in preventing the
phosphorylation of JAK1 and Tyk2 [27,28], and NS2A, NS2B, NS3, NS4A, and NS4B from Kunjin virus
(KUN), a close relative to WNV, are all implicated in JAK-STAT inhibition [73]. This mechanism is
not always mediated by NS proteins, however. Flaviviruses produce small RNAs called subgenomic
flavivirus RNAs (sfRNAs) that are generated by the incomplete degradation of the viral genome by
the host endonuclease XrnI [74]. In DENV, this sfRNA binds to TRIM25, which normally interacts
with RIG-I to promote its ubiquitination and interaction with mitochondrial antiviral signaling protein
(MAVS) [75]. The DENV sfRNA prevents the deubiquitination of TRIM25, an essential upstream
activator for RIG-I activation [76].
Another mechanism of active interference with the type I IFN system is competitive binding.
DENV and WNV NS3 proteins compete with RIG-I for 14-3-3ε binding, a chaperone responsible
for trafficking RNA-bound RIG-I to the mitochondrial membrane [77]. Additionally, the DENV
NS4A protein sequesters MAVS, preventing RIG-I-MAVS interaction, IRF3 activation, and IFN-I
production [78].
Finally, many flavivirus NS proteins have evolved mechanisms to degrade host immune proteins,
or to induce the degradation of these proteins by hijacking the host proteasome system. For example,
the DENV NS2B/NS3 viral protease suppresses the DNA sensing pathway and RIG-I sensing by
cleaving STING, resulting in reduced type I IFN production [21]. Additionally, NS2B by itself promotes
the autophagy-lysosome-dependent degradation of cGAS [21].
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6. NS5 Structure and Function
NS5 is the most conserved flavivirus protein, with less than 45% amino acid difference reported
among the vector-borne flaviviruses [3]. The N-terminus encodes the viral methyltransferase (MTase),
while the C-terminus encodes the RNA-dependent RNA polymerase (RdRp) [79]. The RdRp
generates positive- and negative-sense RNAs from the RNA genome de novo [80,81], and the
replication process is thought to involve three different conformational states: pre-initiation, initiation,
and elongation [82,83]. The MTase domain caps the RNA genome via a two-step reaction and also
serves as the guanylyltransferase [29].
To date, structures of full-length NS5 from JEV [84], DENV3 [85], and ZIKV [79,86,87] have
been reported. The ZIKV and JEV NS5 conformations exhibit a high degree of similarity, suggesting
structural conservation among the flaviviruses [79]. In contrast, the domain orientations of ZIKV and
DENV NS5s differ significantly, although the residues at the domain interface are highly conserved
among ZIKV, DENV, and JEV [79]. These observations support an earlier observation that the
flavivirus NS5 exhibits a high degree of flexibility in solution and can adopt a compact or extended
conformation [88], which may impact on the diverse functions of NS5. Indeed, mutagenesis of the
conserved interface residues of the DENV3 NS5 caused enhanced RdRp activity, but inhibited viral
infectivity [85]. Furthermore, recent structural evidence suggests that the two subdomains cooperate
in the execution of the sequential replication and capping functions, although the mechanism remains
unknown [84,89]. Taken together, these reports suggest that the flexibility and distinct conformations
of the flavivirus NS5 may be linked to the various steps involved in RNA capping and replication.
More experiments are needed to clarify the potential role of the conformational changes in regulating
NS5 activities.
Several post-translational modifications of flavivirus NS5s have also been documented with
potential regulatory roles. Serine/threonine phosphorylation appears to be conserved throughout the
Flaviviridae family [90,91], but the function of this modification and the identity of the host kinases
involved are largely unknown. The DENV NS5 protein is phosphorylated by both mammalian
and mosquito protein kinase G at a conserved Thr449 in the RdRp domain [92,93]. The differential
phosphorylation of DENV NS5 was shown to affect its interaction with the viral helicase, NS3, which is
required for genome replication [94]. The WNV NS5 MTase domain is also phosphorylated by,
and interacts with, protein kinase G, and abolishing this interaction inhibits viral replication [95].
SUMOylation of the DENV NS5 was shown to be important for DENV replication [96]. In addition,
glutathionylation of the DENV and ZIKV NS5s has been reported [97].
Replication of the flavivirus genome occurs exclusively in the cytoplasm [69,98]. However,
a significant portion of the NS5 protein is observed within the nucleus during YFV [99], JEV [100],
ZIKV [3], WNV [101], and DENV [102] infections. Inhibiting the nuclear localization of DENV and
WNV NS5 significantly decreases viral titers [101,103]. Inversely, inhibiting the nuclear export of DENV
NS5 decreased the induction of IL-8, which plays a role in induction of inflammation [104], suggesting
nuclear localization of NS5 may be important for immune modulation [105]. This observation is
further supported by a study showing that interaction of NS5 with host spliceosome components
leads to changes in mRNA isoform abundance of antiviral factors [106]. There are differences,
however, in the level of NS5 nuclear localization among the different DENV serotypes. NS5 from
serotypes 2 and 3 accumulate in the nucleus, while DENV1 and 4 NS5 reside in the cytoplasm [107].
For serotype 4, cytoplasmic localization is likely due to the lack of a functional nuclear localization
signal (NLS) [107]. Levels of IL-8 did not change with the different serotypes, and the function of the
differential localization is still unknown [107].
7. IFN Suppressor Function of Flavivirus NS5 Protein
While multiple proteins capable of IFN antagonism have been described for the major
disease-causing flaviviruses, NS5 is the most potent and direct antagonist [3]. This is significant
because NS5-mediated IFN antagonism is required for counteraction of IFN in cell culture [108] and
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for virulence in mouse models [109]. Remarkably, even though this protein utilizes similar MTase
and RdRp mechanisms no matter the flavivirus species to replicate and cap their RNA genomes,
the mechanism of NS5-mediated IFN suppression diverges within the genus. The evolution and
divergence of this role for NS5 may have been facilitated by the strategy of expression of flaviviral
proteins from a single open reading frame. This results in excess expression of NS5, while only small
amounts are needed for RdRp and MTase functions. Due to the lack of high-resolution structures for
the complexes of various NS5s and their interacting host partners, how NS5 is able to retain its roles as
MTase and RdRp while evolving divergent IFN suppression mechanisms remains elusive.
NS5 frequently employs multiple strategies to suppress the JAK-STAT signaling pathway not only
among different species of Flavivirus, but also within the same species. For example, the ZIKV NS5
protein has been shown to both inhibit the phosphorylation of STAT1 and induce the degradation of
STAT2. The JEV, DENV, and WNV NS5 proteins have similarly been shown to antagonize this pathway
at multiple steps. STAT2 is a common target for NS5-mediated IFN suppression, and at least two
flavivirus NS5 proteins have been demonstrated to target this protein for degradation. The mechanisms
by which the DENV and ZIKV NS5s degrade STAT2 diverge, however, and the molecular details of
these mechanisms are still being elucidated.
7.1. Dengue Virus
DENV NS5 binds to human STAT2 and inhibits its phosphorylation, resulting in reduced ISG
transcription. The mechanism of this inhibition has not been elucidated, but the IFN suppression
activity was mapped to the RdRp domain [110]. Expression of NS5 also reduces IFN-α-, but not IFN-γ-,
mediated STAT1 phosphorylation, although NS5 does not directly interact with STAT1 [110].
Ashour et al. demonstrated STAT2 degradation as an additional mechanism of DENV
NS5-mediated IFN antagonism [111,112]. However, while this study also found that binding of NS5 to
STAT2 is sufficient to prevent IFN signaling, STAT2 degradation is detected only when the N-terminus
of NS5 is proteolytically processed, as it would be in the context of viral infection. NS5 is separated
from NS4B during polyprotein processing by the viral NS2B/NS3 protease, and co-expression of
NS5 with NS2B/NS3 induces STAT2 degradation. Replacement of the viral cleavage site at the
N-terminus of NS5 with a host protease cleavage site, however, also allows for the efficient degradation
of STAT2, suggesting the cleavage does not need to be mediated by the viral protease. Additionally,
the identity of the N-terminal residue of NS5 does not appear to be important to this processing
event, as replacing the glycine residue at position 1 of NS5 with methionine resulted in efficient STAT2
degradation [112]. This study also demonstrated that NS5-mediated STAT2 degradation is dependent
on the ubiquitin-proteasome pathway, implying the involvement of a host E3 ligase. In a follow-up
study, the García-Sastre group identified this protein as UBR box N-recognin-4 (UBR4), which is part
of the N-recognin family [113]. Members of this family target proteins that undergo conformational
changes to expose a destabilizing N-terminal residue for degradation, a mechanism for the N-end rule
pathway [114]. UBR4 binds to the first five amino acids of NS5; deleting the first ten amino acids of NS5
eliminates its ability to induce STAT2 degradation [112,113]. The binding domain for STAT2, however,
was mapped to residues 202–306 [112], suggesting that the DENV NS5 central and N terminal regions
together serve as a bridge between STAT2 and UBR4. In this scenario, it is possible that NS5 and STAT2
are both targeted by UBR4 and similarly degraded [7]. Experimental evidence, however, is still needed
for verification of the role of the N-end rule pathway in DENV NS5-mediated STAT2 degradation.
7.2. Zika Virus
Similar to DENV NS5, ZIKV NS5 binds to human STAT2, triggering its degradation. However,
unlike what was observed for DENV NS5, ZIKV NS5 does not need to undergo proteolytic processing
for depletion of STAT2 [3]. Additionally, it was demonstrated that the first ten amino acids of NS5 are
dispensable for depletion of STAT2, suggesting that the N-end rule does not apply to ZIKV NS5 [115].
STAT2 is ubiquitinated prior to degradation, and proteasome inhibitors rescue STAT2 protein levels
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in the presence of NS5 [65]. However, unlike that occurs for DENV NS5, UBR4 is not involved in
mediating STAT2 degradation [3]. This suggests that ZIKV NS5-mediated STAT2 degradation utilizes
the host ubiquitin proteasome system and the participating host E3 ligase has yet to be identified.
Chaudhary et al. demonstrated an additional consequence of ZIVK NS5-mediated STAT2
degradation, aside from decreased ISG induction. In an uninfected cell, unphosphorylated STAT2
can bind to both unphosphorylated and phosphorylated STAT1 to prevent translocation of STAT1
and activation of the type II IFN response [116]. In ZIKV-infected and NS5-transfected cells, however,
an increase in STAT1 homodimerization is observed, concurrent with an increase in type II IFN and
a decrease in type I IFN signaling. In this model, the degradation of STAT2 frees up STAT1 proteins
to homodimerize and translocate to the nucleus to selectively activate ISGs controlled by gamma
activated sites (GAS) [65].
7.3. Yellow Fever Virus
The YFV NS5 also targets STAT2 as part of its IFN-I suppression mechanism. YFV NS5 binds
to STAT2, but this interaction is uniquely dependent on host cell stimulation with type I or III IFNs.
This stimulation induces several intracellular events required for NS5 association with STAT2. First,
as in an uninfected cell, stimulation with IFN induces the phosphorylation and heterodimerization
of STAT1 and STAT2. STAT2 does not need to be phosphorylated for NS5 interaction. Instead,
the association of STAT1 and STAT2 induces a conformational change within STAT2 that allows
for NS5 binding. Second, IFN stimulation promotes the ubiquitination of YFV NS5 by TRIM23;
non-ubiquitinated NS5 cannot interact with STAT2. Unlike the DENV and ZIKV NS5s, YFV NS5 does
not induce the degradation of STAT2, and is able to bind STAT2 both in the cytoplasm and in the
nucleus. YFV NS5 blocks IFN production either by directly interfering with ISGF3 binding to ISRE
promoter elements in the nucleus, or by preventing IRF9 association with STAT1/2 heterodimers
in the cytoplasm. A domain mapping study identified the first ten amino acids of the YFV NS5 as
essential for both STAT2 interaction and IFN-I inhibition, consistent with the requirement of TRIM23
ubiquitinating K6 of NS5 [117].
8. Other NS5 Interactions
8.1. Spondweni Virus
Spondweni virus (SPOV) is the closest known relative of ZIKV [118], and their NS5 proteins share
77% amino acid identity [3]. While SPOV NS5 does not directly interact with STAT2 as the ZIKV NS5
does, it is an inhibitor of JAK-STAT signaling, as SPOV NS5-transfected cells inhibit ISRE-dependent
gene expression [3]. The STATs are also phosphorylated and translocated to the nucleus upon IFN
stimulation. SPOV NS5 is localized primarily to the nucleus of the cell, so it is possible the mechanism
of ISG suppression occurs inside the nucleus [3].
8.2. Japanese Encephalitis Virus
The JEV NS5 protein alone can inhibit Tyk2 and STAT1 phosphorylation via protein tyrosine
phosphatase (PTP) activity, as PTP inhibitors rescue phosphorylation, but specific NS5 interactions
with innate immune proteins have not yet been implicated in this suppression mechanism [119].
The region of NS5 required for suppression of STAT1 activation was mapped to the N terminus [119].
JEV NS5 has also been shown to inhibit the nuclear translocation of IRF3 and NF-κB by competitively
interacting with importin-α4 and importin-α3 [120]. These interactions are mediated by the NLS of
JEV NS5 and mutagenesis of key residues in this region restored ISG expression [120].
8.3. Tick-Borne Encephalitis, Langat, and West Nile Viruses
Langat virus (LGTV) is a member of the tick-borne encephalitis virus (TBEV) serogroup.
Both LGTV and TBEV NS5s suppress phosphorylation of STAT1, STAT2, Tyk2, and JAK1 [121].
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The region of LGTV NS5 responsible for this suppression mechanism was mapped to the RdRp
domain of NS5 [122]. The minimal linear sequence required was mapped to residues 355–735 which
overlap with the finger region and the eight conserved RdRp motifs [122]. The specific amino acids
required lay within two noncontiguous stretches of amino acids: 374–380 within the finger domain
and 624–647 within the palm domain [122]. When modeled on the crystal structure of the WNV RdRp,
these two amino acid stretches are adjacent to one another, suggesting cooperative action [122].
It was later determined that LGTV and TBEV NS5s also interact with prolidase (PEPD), a host
protein that is required for IFNAR1 maturation [109]. This interaction was mapped to the same
region as that required for LGTV NS5-mediated STAT1 phosphorylation inhibition [121]. STAT1,
STAT2, Tyk2, and JAK1 phosphorylation occur downstream of IFNAR1, so this NS5 interaction
elucidated the mechanism of NS5-mediated IFN suppression in addition to the mechanism of IFNAR1
downregulation. LGTV and TBEV NS5s are also known to interact with IFNAR2 and IFNGR1, but the
function of these interactions is still unknown [121].
TBEV NS5 has also been shown to interact with the mammalian membrane protein Scribble which
has been implicated in T cell activation [123]. The interaction was mapped to the MTase domain of
TBEV NS5 and the PSD-95, Discs-large, ZO-1 domain 4 (PDZ4) of Scribble [123]. In IFN-stimulated
cells depleted for Scribble, phosphorylation and nuclear localization of STAT1 was restored [123].
WNV NS5, like LGTV and TBEV, was also shown to interact with PEPD to downregulate IFNAR
expression [110]. This interaction may be the mechanism by which WNV NS5 inhibits STAT1 and
STAT2 phosphorylation, but further investigation is required for this conclusion [3,108].
9. Summary
Effective inhibition of type I IFN production is necessary for flaviviruses to establish infection in
mammalian hosts. The viral non-structural proteins have evolved to be multi-functional, encoding
diverse IFN suppression mechanisms in addition to their essential roles in the viral life cycle.
NS5 is one of the most important IFN-I antagonists. Three of the most pervasive disease-causing
flaviviruses—YFV, ZIKV, and DENV—inhibit human STAT2 through NS5-hSTAT2 interaction.
Detailed mechanistic understanding of these interactions provides at least two opportunities for
translational research. First, recombinant viruses that incorporate loss-of-function mutations in NS5 are
attractive candidates for live-attenuated vaccine strains. Second, antivirals that target the NS5-hSTAT2
interaction would inhibit an early step common to these flaviviruses, despite divergent downstream
mechanisms employed by the NS5s. These applications require deeper mechanistic understandings of
the interaction between NS5 and hSTAT2.
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